Tanner Pharma Group and Biodexa Introduce Global Early Access Initiative for Patients with Familial Adenomatous Polyposis (FAP)
Tanner Pharma Group, a globally recognized provider of specialty medicine access solutions, has entered into a strategic partnership with Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal cancers. This collaboration is aimed at enabling global patient access to eRapa, an investigational therapy for individuals diagnosed with Familial Adenomatous Polyposis (FAP), through a structured Early Access or Named Patient Program.
The partnership reflects a growing trend in the pharmaceutical and biotechnology industries to expand access to promising therapies prior to formal regulatory approval, particularly for rare and underserved diseases where treatment options are extremely limited. By leveraging Tanner Pharma Group’s expertise in global access programs and Biodexa’s scientific innovation, the initiative seeks to bridge a critical gap between clinical development and patient need.
Familial Adenomatous Polyposis is a rare, inherited condition characterized by the early development of hundreds to thousands of polyps in the colon and rectum. These polyps typically begin to form during adolescence, often in the mid-teen years, and carry a near-certain risk of progressing to colorectal cancer if left untreated. Due to the aggressive nature of the disease and the lack of approved pharmacological therapies, the current standard of care primarily involves surgical intervention, including colectomy or proctocolectomy, to reduce cancer risk. While effective in preventing malignancy, these procedures are invasive and can significantly impact a patient’s quality of life.
Despite advances in oncology and gastrointestinal research, FAP has remained an area with significant unmet medical need. The absence of approved drug therapies has limited clinicians’ ability to offer non-surgical alternatives, underscoring the importance of investigational approaches such as eRapa.
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus, a compound with well-established biological activity. Rapamycin functions as an inhibitor of the mTOR pathway (mechanistic target of rapamycin), a critical regulator of cellular metabolism, growth, proliferation, and survival. Dysregulation of this pathway has been implicated in a wide range of diseases, including cancer, where it plays a key role in tumor development and progression.
In the context of FAP, research has demonstrated that the mTOR pathway is frequently overexpressed in adenomatous polyps, suggesting that targeted inhibition could help control polyp growth and potentially delay or reduce disease progression. This scientific rationale has driven the development of eRapa as a potential therapeutic option for patients with FAP, offering a novel mechanism of action that addresses the underlying biology of the disease.
Through the newly announced partnership, Tanner Pharma Group will take the lead in facilitating access to eRapa in regions where the therapy is not yet commercially available or approved. The Early Access / Named Patient Program is designed to operate within established regulatory frameworks, ensuring that access is provided in a compliant, ethical, and controlled manner. This approach allows physicians to request the investigational treatment for eligible patients on a case-by-case basis, outside the constraints of formal clinical trials.
For many patients and clinicians, this represents a significant opportunity. Historically, access to investigational therapies has been limited to participation in clinical studies, which may not be available in all geographic regions or accessible to all patients due to strict inclusion criteria. By expanding availability through an early access program, this collaboration enables a broader population of patients to potentially benefit from emerging treatments.
Importantly, the program is not only focused on providing access but also on generating valuable insights into real-world use. As part of the initiative, Biodexa Pharmaceuticals will collect and analyze Real World Data (RWD) from patients receiving eRapa. This data can play a crucial role in enhancing the understanding of FAP, including disease progression, treatment response, and overall patient experience in a non-trial setting.
Real World Data has become an increasingly important component of modern drug development and regulatory decision-making. Unlike traditional clinical trial data, which is generated under controlled conditions, RWD reflects how therapies perform in everyday clinical practice. This can provide a more comprehensive picture of a drug’s safety and effectiveness across diverse patient populations, ultimately supporting future regulatory submissions and clinical adoption.
The global scope of the program is another key strength of the partnership. By making eRapa accessible to clinicians worldwide, Tanner Pharma Group and Biodexa aim to address disparities in healthcare access that often affect patients with rare diseases. However, access through the program will be governed by several factors, including patient eligibility criteria, local regulatory requirements, and the availability of funding from government or private sources.
These considerations are essential to ensure that the program operates responsibly and sustainably. Named Patient Programs must navigate a complex landscape of international regulations, balancing the urgency of patient need with the requirements of safety, compliance, and oversight. Tanner Pharma Group’s experience in managing such programs positions it well to handle these challenges effectively.
From a strategic perspective, this collaboration also aligns with Biodexa’s broader development goals. By enabling early access to eRapa and collecting real-world evidence, the company can further validate the therapeutic potential of its lead candidate while building a foundation for future commercialization. The insights gained through the program may inform ongoing and future clinical studies, as well as support interactions with regulatory authorities.
For patients living with Familial Adenomatous Polyposis, the launch of this program represents a meaningful step forward. While surgical intervention remains the cornerstone of treatment, the availability of an investigational pharmacological option offers new hope for less invasive disease management. If successful, eRapa could potentially change the treatment landscape for FAP, providing an alternative or complementary approach to existing standards of care.
In conclusion, the partnership between Tanner Pharma Group and Biodexa Pharmaceuticals highlights the importance of collaboration in addressing unmet medical needs, particularly in rare diseases. By combining expertise in drug development, global access, and real-world data generation, the two organizations are working to bring a promising investigational therapy to patients who currently have limited options. As the Early Access / Named Patient Program rolls out globally, it has the potential not only to improve individual patient outcomes but also to contribute valuable knowledge that could shape the future of FAP treatment.
About Tanner Pharma Group
Tanner Pharma is a specialist pharmaceutical services provider based in Charlotte, NC, USA with offices in Ireland, Switzerland and the UK. The company focuses on improving global access to medicines and, through its Managed Access Programs division, supports manufacturers by providing controlled and compliant access to innovative therapies in countries where they are not commercially available. For more information, visit www.tannerpharma.com.
About Biodexa Pharmaceuticals PLC
Biodexa is a clinical stage biotechnology company developing treatments for diseases with high unmet need. Its lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 for Gastrointestinal Stromal Tumors (GIST), and tolimidone for type 1 diabetes. Biodexa is headquartered in Cardiff, UK.
Source Link:https://www.businesswire.com/
